ClinicalTrials.gg
Not yet recruitingNCT07733193PREBONEUpdated Jul 29, 2026

Impact of Prophylactic Bone Radiation Therapy in Patients With Bone Metastases.

A Phase 3 interventional study of prophylactic radiation and standard of care in Bone Metastases, sponsored by Centre Henri Becquerel. Not yet recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Centre Henri Becquerel · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 482 studies in Pain with a site in France — 75 open to participants now, 79 under way, 8 of them phase 3. Pain · France.

Planned enrollment
91st of 369
154 · median 80
Started
2026
with 27 others
Phase 3
77 of 482
7 open now
Primary completion
2029-09
later than 74 of 78 live
Registered
479th of 482
by date

Among the 482 studies in Pain with a site in France, this one is the 91st largest by planned enrollment of the 369 interventional ones that give a count, is one of 28 that started in 2026, is one of 77 in phase 3, reaches primary completion later than 74 of the 78 other live ones, and was the 479th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

75 of the 482 studies in Pain with a site in France are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 482 studies in Pain with a site in France, or all of them as a file.
02

Study summary

Radiation therapy is a common treatment for painful bone metastases, proving effective in 1 to 2/3 of cases after 1 to 10 sessions, with stereotactic body radiation therapy (SBRT) likely offering superior results.

Radiation therapy is also used to prevent bone events, although its use is not standardized; the decision to administer it is made by clinicians or through multidisciplinary team (MDT) discussions.

Recently, it has been shown that preventive radiation therapy can reduce the risk of skeletal-related events (SREs) in patients at high risk for bone events.

The objective is to compare active surveillance with preventive radiation therapy in patients at intermediate risk for bone events.

03

Conditions studied

  • Bone Metastases

Browse trials for

Keywords

  • prophylactic radiation
  • bone metastases
  • pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women, 18 years of age or older
  • Patients with solid cancer and bone
  • Patients with bone lesions considered to be at intermediate risk for skeletal-related events (SINS score between 7 and 12, Mirels 8) or patients with lesions accompanied by Grade 1 epiduritis (Bilsky)
  • Enrolled in or covered by a social insurance program
  • Patients with an estimated of more than 6 months

Exclusion criteria

Exclusion Criteria:

  • Hematologic disease
  • Patients with a lesion at high risk for skeletal-related events (SINS score of 13 or higher, MIRELS score of 9 or higher, or a multidisciplinary team (MDT) recommendation that surgery is necessary)
  • Patients with pain secondary to bone lesions requiring radiation therapy
  • to radiation therapy due to a history of radiation therapy at the same site or a condition contraindicating radiation therapy
  • Pregnant or breastfeeding women
  • Contraindication to MRI in cases of spinal lesions; contrast-enhanced CT scan
  • Patients unable to understand the study for any reason or to comply with the trial requirements (language, psychological, geographic issues, etc.)
  • Patients under legal guardianship or conservatorship
  • Patients classified as WHO 3 or 4
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (estimated)

Study arms

  • Active comparator
    Standard arm

    no bone radiation for patient allocated in this arm

    Drug: standard of care

  • Experimental
    Prophylactic radiation

    patient undergo prophylactic radiation on bone metastases

    Radiation: prophylactic radiation

Interventions

  • Radiationprophylactic radiation

    Patients will undergo propthylactic radiation on bone metastases

  • Drugstandard of care

    Patients will have systemic treatment on the standard of care

06

What researchers measure

Primary outcomes

  1. Bone event

    rate of bone event in the two arms

    Time frame: one year

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2029, 36 months later.

Of 111 non-industry phase 3 interventional studies under Pain, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 36 months is above that.

Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 29, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Sep 1, 2029
CompletionEst.
Nov 1, 2030
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07733193
Lead sponsor
Centre Henri Becquerel
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 1, 2029 (estimated)
Completion
Nov 1, 2030 (estimated)
Last update
Jul 29, 2026

Study contacts

Sebastien Thureau, MD, PhD
Contact
sebastien.thureau@chb.unicancer.fr
+0232082985
Doriane Richard, PhD
Contact
doriane.richard@chb.unicancer.fr
+33232082985
Sebastien Thureau, MD, PhD
study director · Centre Henri Becquerel

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion